Anti-VHH domain antibodies and use thereof
AssigneeNanjing GenScript Biotech Co., Ltd.
InventorsXijian Qin, Liwei Sun, Wanyi Wang, Guangwei Song
Life of this patent
Estimating the term…
Abstract
The invention provides a group of anti-VHH domain antibodies and use thereof. The present invention further provides use of the described antibodies in the development, screening and purification of nano-antibodies, and use of the described antibodies in the field of immunotherapy.
Claims18
An antibody or antigen-binding fragment thereof, wherein the antibody contains a heavy chain variable region and a light chain variable region, wherein (A) the heavy chain variable region comprises heavy chain complementarity determining region (HCDR) 1, HCDR2 and HCDR3, and (B) the light chain variable region comprises light chain complementarity determining region (LCDR) 1, LCDR2, and LCDR3, wherein the antibody contains
- (1) HCDR1 shown in SEQ ID NO:
- 14, HCDR2 shown in SEQ ID NO:
- 29, HCDR3 shown in SEQ ID NO:
- 44, LCDR1 shown in SEQ ID NO:
- 59, LCDR2 shown in SEQ ID NO:
- 74 and LCDR3 shown in SEQ ID NO:
- 89;
- (2) HCDR1 shown in SEQ ID NO:
- 4, HCDR2 shown in SEQ ID NO:
- 19, HCDR3 shown in SEQ ID NO:
- 34, LCDR1 shown in SEQ ID NO:
- 49, LCDR2 shown in SEQ ID NO:
- 64 and LCDR3 shown in SEQ ID NO:
- 79;
- (3) HCDR1 shown in SEQ ID NO:
- 15, HCDR2 shown in SEQ ID NO:
- 30, HCDR3 shown in SEQ ID NO:
- 45, LCDR1 shown in SEQ ID NO:
- 60, LCDR2 shown in SEQ ID NO:
- 75 and LCDR3 shown in SEQ ID NO:
- 90;
- (4) HCDR1 shown in SEQ ID NO:
- 1, HCDR2 shown in SEQ ID NO:
- 16, HCDR3 shown in SEQ ID NO:
- 31, LCDR1 shown in SEQ ID NO:
- 46, LCDR2 shown in SEQ ID NO:
- 61 and LCDR3 shown in SEQ ID NO:
- 76;
- (5) HCDR1 shown in SEQ ID NO:
- 2, HCDR2 shown in SEQ ID NO:
- 17, HCDR3 shown in SEQ ID NO:
- 32, LCDR1 shown in SEQ ID NO:
- 47, LCDR2 shown in SEQ ID NO:
- 62 and LCDR3 shown in SEQ ID NO:
- 77;
- (6) HCDR1 shown in SEQ ID NO:
- 3, HCDR2 shown in SEQ ID NO:
- 18, HCDR3 shown in SEQ ID NO:
- 33, LCDR1 shown in SEQ ID NO:
- 48, LCDR2 shown in SEQ ID NO:
- 63 and LCDR3 shown in SEQ ID NO:
- 78;
- (7) HCDR1 shown in SEQ ID NO:
- 5, HCDR2 shown in SEQ ID NO:
- 20, HCDR3 shown in SEQ ID NO:
- 35, LCDR1 shown in SEQ ID NO:
- 50, LCDR2 shown in SEQ ID NO:
- 65 and LCDR3 shown in SEQ ID NO:
- 80;
- (8) HCDR1 shown in SEQ ID NO:
- 6, HCDR2 shown in SEQ ID NO:
- 21, HCDR3 shown in SEQ ID NO:
- 36, LCDR1 shown in SEQ ID NO:
- 51, LCDR2 shown in SEQ ID NO:
- 66 and LCDR3 shown in SEQ ID NO:
- 81;
- (9) HCDR1 shown in SEQ ID NO:
- 7, HCDR2 shown in SEQ ID NO:
- 22, HCDR3 shown in SEQ ID NO:
- 37, LCDR1 shown in SEQ ID NO:
- 52, LCDR2 shown in SEQ ID NO:
- 67 and LCDR3 shown in SEQ ID NO:
- 82;
- (10) HCDR1 shown in SEQ ID NO:
- 8, HCDR2 shown in SEQ ID NO:
- 23, HCDR3 shown in SEQ ID NO:
- 38, LCDR1 shown in SEQ ID NO:
- 53, LCDR2 shown in SEQ ID NO:
- 68 and LCDR3 shown in SEQ ID NO:
- 83;
- (11) HCDR1 shown in SEQ ID NO:
- 9, HCDR2 shown in SEQ ID NO:
- 24, HCDR3 shown in SEQ ID NO:
- 39, LCDR1 shown in SEQ ID NO:
- 54, LCDR2 shown in SEQ ID NO:
- 69 and LCDR3 shown in SEQ ID NO:
- 84;
- (12) HCDR1 shown in SEQ ID NO:
- 10, HCDR2 shown in SEQ ID NO:
- 25, HCDR3 shown in SEQ ID NO:
- 40, LCDR1 shown in SEQ ID NO:
- 55, LCDR2 shown in SEQ ID NO:
- 70 and LCDR3 shown in SEQ ID NO:
- 85;
- (13) HCDR1 shown in SEQ ID NO:
- 11, HCDR2 shown in SEQ ID NO:
- 26, HCDR3 shown in SEQ ID NO:
- 41, LCDR1 shown in SEQ ID NO:
- 56, LCDR2 shown in SEQ ID NO:
- 71 and LCDR3 shown in SEQ ID NO:
- 86;
- (14) HCDR1 shown in SEQ ID NO:
- 12, HCDR2 shown in SEQ ID NO:
- 27, HCDR3 shown in SEQ ID NO:
- 42, LCDR 1 shown in SEQ ID NO:
- 57, LCDR2 shown in SEQ ID NO:
- 72 and LCDR3 shown in SEQ ID NO:
- 87;
- or
- (15) HCDR1 shown in SEQ ID NO:
- 13, HCDR2 shown in SEQ ID NO:
- 28, HCDR3 shown in SEQ ID NO:
- 43, LCDR1 shown in SEQ ID NO:
- 58, LCDR2 shown in SEQ ID NO:
- 73 and LCDR3 shown in SEQ ID NO:
- 88.
Dependencies are inferred from the claim text.